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BACKGROUND: Anti-angiogenic therapy with bevacizumab (an anti-vascular endothelial growth factor (VEGF) antibody) predominantly
targets immature blood vessels. Bevacizumab has shown a survival benefit in non-small cell lung carcinoma (NSCLC) and has recently
been demonstrated to be safe in patients with brain metastases. However, it is not known whether bevacizumab is effective against
brain metastases or whether metastases are representative of their primary in terms of VEGF expression, hypoxia, proliferation and
vascular phenotype. The aim of this study was to evaluate these factors in a series of matched primary NSCLCs and brain metastases.
METHODS ANDRESULTS: Immunohistochemistry showed strong correlation of carbonic anhydrase 9 expression (a marker of hypoxia) in
primary and secondary cancers (P¼0.0002). However, the proliferation index, VEGF expression, microvessel density and the
proportion of mature vessels were discordant between primary and secondary cancers. The mean proportion of mature vessels was
63.2% higher in the brain metastases than the primary tumours (P¼0.004). Moreover, the vascular pattern of the primary tumour
was not representative of the metastasis.
CONCLUSIONS: Brain metastases have a significantly higher proportion of mature vasculature, suggesting that they may be refractory to
anti-VEGF therapy. These findings may have implications for clinical trials and biomarker studies evaluating anti-angiogenic agents in
brain metastases.
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Angiogenesis, the development of new blood vessels, is a feature
common to many carcinomas and has been proposed as a
hallmark of cancer (Hanahan and Weinberg, 2000). However,
morphological assessment of lung carcinomas has revealed that
they may be subdivided into angiogenic and relatively non-
angiogenic tumours (Pezzella et al, 1997); the latter co-opt
pre-existing vasculature to support an alveolar pattern of growth.
Nevertheless, the majority of non-small cell lung carcinomas
(NSCLCs) are angiogenic and express vascular endothelial growth
factor-A (VEGF) (Jubb et al, 2004), the predominant pro-
angiogenic ligand that is exploited by tumours (Kerbel, 2008).
Animal models (Kim et al, 1993; Huang et al, 2004; Mancuso et al,
2006) and human studies (Willett et al, 2004) have shown that
blocking VEGF signalling results in tumour shrinkage, associated
with the pruning of angiogenic (proliferative, leaky and immature
(i.e., without associated pericytes)) blood vessels. This observation
led to the development of a humanised anti-VEGF monoclonal
antibody, bevacizumab, which has shown an improved progres-
sion-free survival benefit in numerous tumour types (Hurwitz
et al, 2004; Miller et al, 2007; Rini et al, 2010).
In recurrent or advanced NSCLC, the addition of bevacizumab
to carboplatin and paclitaxel chemotherapy (E4599 study) resulted
in a 2-month improvement in median overall survival (Sandler
et al, 2006). When combined with cisplatin and gemcitabine
(AVAiL study) in NSCLC, bevacizumab showed no improvement
in overall survival, but demonstrated improved progression-
free survival (Reck et al, 2010). The E4599 study excluded patients
with brain metastases due to concerns that bevacizumab might
exacerbate the incidence of tumour-associated brain haemorrhage
(Sandler et al, 2006). Several analyses now suggest that bevacizu-
mab is safe in patients with brain metastases (Socinski et al, 2009;
Besse et al, 2010), but there is no evidence regarding the efficacy of
bevacizumab in this indication. Indeed, there is little published on
the vascular phenotype, VEGF expression, hypoxia and prolifera-
tion of NSCLC brain metastases, which may inform efficacy.
To date, no valid biomarkers of the survival benefit of
bevacizumab have been identified. Objective response rates have
been shown not to predict benefit from bevacizumab in colorectal
cancer (Grothey et al, 2008), and there are concerns that changes
in the MRI appearance of glioblastoma following bevacizumab
treatment do not predict clinical benefit (Gerstner et al, 2010).
Efforts to identify novel in situ biomarkers of efficacy have focused
on available tissue samples from primary tumour resections (Ince
et al, 2005; Jubb et al, 2006), to make inferences concerning the
treatment of metastatic disease. However, while there is evidence
to support this for metastatic colorectal cancer (Kuramochi et al,
2006), there is little evidence to suppose that this is a valid
approach to inform the biology of NSCLC brain metastases.
Received 7 February 2011; revised 5 April 2011; accepted 6 April 2011;
published online 3 May 2011
*Correspondence: Dr AM Jubb; E-mail: adrianjubb@gmail.com
British Journal of Cancer (2011) 104, 1877–1881
& 2011 Cancer Research UK All rights reserved 0007– 0920/11
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sIn summary, a greater understanding of the vascular phenotype
of NSCLC brain metastases may better inform the use of anti-
angiogenic agents in this indication. The aim of this study was to
assess the relative expression of VEGF, hypoxia, proliferation,
microvessel density, vascular pattern and vascular maturity in a
series of matched primary NSCLCs and brain metastases.
MATERIALS AND METHODS
Tissue
Formalin-fixed paraffin-embedded blocks for 15 cases of primary
NSCLC with matched resected brain metastases were retrieved
from the pathology archives at the Catholic University Hospital,
Rome. Ethical approval for this research was granted by the local
research ethics committees.
Immunohistochemistry
Characterisation of the antibodies and immunohistochemical
methods for VEGF (Turley et al, 1998), CA9 (Jubb et al, 2009),
Ki67 (Sington et al, 2007), CD34 (Kuzu et al, 1992) and CD34 and
smooth muscle actin (SMA) (double stain; QBEnd/10 and 1A4;
Dako, Ely, UK) (Patel et al, 2006) have been described in detail
elsewhere.
Scoring
The maximum intensity of VEGF expression in 410% of tumour
cells was recorded on a semiquantitative scale from 0 (no
expression) to 3 (very strong expression). The percentage of
tumour cells with membranous expression of CA9 was estimated
by a pathologist. The percentage of tumour cells with nuclear
positivity for Ki67 was counted by a pathologist. Microvessel
density analysis was performed using the Chalkley method; at low
power ( 40), five vascular hotspots in CD34-labelled sections
were selected. Microvessel density was assessed by counting the
number of CD34-labelled vessels that overlapped with dots on a
25-point Chalkley eyepiece graticule in each high-power field
( 200) (Fox et al, 1995). The five counts were then added together
to provide the density score. Vascular maturity is defined by
the coverage of endothelial cells (CD34 positive) by pericytes
(SMA positive) and was calculated by counting the proportion of
CD34-labelled vessels that were surrounded, at least in part, by
SMA-labelled cells from 10 high-power fields ( 400). Each case
was classified according to the predominant vascular pattern
(alveolar, basal, diffuse or papillary) described elsewhere (Pezzella
et al, 1997). All scoring was performed blind to the patients’
identities.
Statistical analyses
Student’s t-test was used to assess the difference between subsets
of continuous data and Spearman’s correlation coefficient was
used to assess covariance. The w
2 test was used to evaluate
associations between categorical data and Cohen’s k statistic was
used to determine agreement.
RESULTS
Chalkley counts in primary NSCLCs and brain metastases were not
significantly correlated (r¼0.148, P¼0.60) (Table 1; Figure 1).
Although, mean Chalkley counts were similar in primary and
secondary cancers (42.5 vs 43.5, respectively, P¼0.77). The
proportion of mature vessels was on average 63.2% greater in
brain metastases than their matched primary NSCLCs (mean
25.7% vs 88.9%, respectively, P¼0.004) (Table 1; Figure 1). The
proportions of mature vessels in primary and secondary cancers
were not significantly correlated (r¼ 0.46, P¼0.09). Differences
were also observed in vascular patterns, with a predominance of
alveolar, basal and diffuse patterns in primary tumours and a
predominance of diffuse and papillary patterns in secondary
tumours (Table 1).
The percentage of CA9-positive tumour cells was similar to that
previously reported (Giatromanolaki et al, 2001) and was closely
correlated between primary NSCLCs and brain metastases
(r¼0.825, P¼0.0002), suggesting that there were similar levels
of hypoxia in matched cases from this series (Table 1; Figure 1).
The mean percentage of cells positive for CA9 was not statistically
significantly different in primary and secondary cancers (14.0 vs
10.7, respectively, P¼0.27). Vascular endothelial growth factor
expression was seen in all primary and secondary NSCLCs;
however, there was no agreement between the scores in matched
Table 1 Scoring frequencies
Case
VEGF intensity
score (0 to 3)
CA9
(% positive)
Ki67
(% positive)
Chalkley
count (n)
Vascular maturity
(% mature)
Vascular
pattern
Site Lung Brain Lung Brain Lung Brain Lung Brain Lung Brain Lung Brain
1 2 2 0 20 10 50 34 51 36 96 Basal Papillary
2 2 1 0 0 50 50 45 43 21 88 Basal Basal
3 2 3 0 0 10 30 39 35 23 97 Basal Papillary
4 2 3 0 0 0 15 44 62 4 97 Alveolar Papillary
5 2 2 30 20 60 80 44 47 4 93 Diffuse Basal
6 1 2 5 0 20 15 45 44 14 95 Alveolar Diffuse
7 2 3 0 0 40 30 33 53 27 94 Basal Basal
8 2 2 10 15 0 70 24 18 9 58 Diffuse Diffuse
9 2 2 0 0 40 40 57 45 61 86 Papillary Papillary
10 2 1 0 0 0 20 40 56 30 88 Alveolar Diffuse
11 1 2 30 20 10 5 43 25 30 97 Diffuse Diffuse
12 2 3 80 50 30 10 63 55 28 77 Alveolar Papillary
13 2 1 50 30 5 40 43 39 40 89 Basal Diffuse
14 1 2 5 5 5 40 48 35 12 94 Diffuse Papillary
15 3 1 0 0 10 40 36 44 47 84 Basal Diffuse
Median 2 2 0 0 10 40 43 44 27 93 NA NA
IQR 2–2 1.5–2.5 0–20 0–20 5–35 17.5–45 37.5–45 37–52 13–33 87–95.5 NA NA
Abbreviations: CA9¼carbonic anhydrase 9; IQR¼interquartile range; NA¼not applicable; VEGF¼vascular endothelial growth factor.
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spairs (k¼ 0.25) and the association was not statistically
significant (P¼0.15) (Table 1; Figure 1). The proliferative fraction
(percentage of Ki67-labelled cells) was also not significantly
correlated between primary and secondary cancers (r¼0.179,
P¼0.524), though the mean Ki67 was significantly higher in the
brain metastases than the primary lung cancers (35.7% vs 19.3%,
respectively, P¼0.018) (Table 1).
DISCUSSION
This is the first report comparing VEGF expression, CA9
expression, proliferation, microvessel density, vascular pattern
and vascular maturity in matched primary NSCLCs and brain
metastases. The data show that brain metastases have a
significantly greater proliferation rate and vascular maturity than
their matched primaries. Neither the proliferation rate, vascular
maturity, expression of VEGF, vascular pattern nor microvessel
density could be predicted in the brain metastasis from examina-
tion of the primary NSCLC. Only CA9 expression showed a strong
correlation between primary and secondary NSCLCs. These
observations are important for the following reasons:
First, anti-VEGF therapies were thought to increase the risk of
cerebral haemorrhage in patients with brain metastases, but recent
data suggest that bevacizumab is safe in this indication. Our data
provide a biological explanation for this observation, showing that
the vasculature of brain metastases is stable, and (extrapolating
from observations in rectal cancer) (Willett et al, 2004) is unlikely
to regress following anti-VEGF therapy, minimising the risk of
associated haemorrhage.
Second, mature vasculature is less sensitive to anti-VEGF
therapy, suggesting that while patients with primary NSCLCs
may benefit from anti-VEGF therapy, those with brain metastases
may not. Moreover, preclinical data suggest that when endothelial
regression is seen in mature vessels targeted by anti-VEGF therapy,
a pericyte scaffold remains and permits rapid re-angiogenesis
following cessation of therapy (Mancuso et al, 2006). Thus, a
rebound effect may be expected if anti-VEGF therapy is used in
brain metastases and continuous, rather than intermittent, therapy
might show greater efficacy. No efficacy data exist for bevacizumab
in brain metastases, but Socinski et al (2009) have stated that
‘patients with treated brain metastases will likely derive similar
benefit from bevacizumab as patients without brain metastases’
without any biological, pathological or clinical evidence. The data
herein are an important counterbalance to this claim.
Third, non-angiogenic NSCLCs (Pezzella et al, 1997) that show
an alveolar pattern of growth may metastasize, and do not merely
co-opt existing vasculature in the brain, but instead develop a
more angiogenic phenotype with haphazardly arranged vessels.
Moreover, even non-angiogenic, alveolar tumours express VEGF,
are under the influence of hypoxia and are supported by an often
immature, dense vasculature. Therefore, one may expect non-
angiogenic tumours to potentially respond to anti-VEGF therapy at
their site of origin.
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Figure 1 (A) A scatter plot of CD34 Chalkley counts in matched primary (lung) and secondary (brain) cancers. (B) A line plot showing differences in the
percentage of blood vessels covered by pericytes in matched primary and secondary cancers. (C) A scatter plot of the percentage of matched primary and
secondary cancers positive for carbonic anhydrase 9. (D) A line plot showing differences in the VEGF score in matched primary and secondary cancers.
(E, F) Double-labelled immunohistochemistry for CD34 (blue) and smooth muscle actin (brown) in a matched primary (E) and secondary (F) cancer.
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from trials of anti-VEGF therapy have thus far failed to identify a
biomarker of efficacy (Jubb and Harris, 2010). The data presented
herein suggest that the vascular phenotypes of primary and
secondary cancers are very different. Therefore, when evaluating
anti-angiogenic treatments in the metastatic setting, biomarker
studies should also be conducted on metastases and not the
primary tumours.
The limitations of this study include the sample size, which is
small in statistical terms, but it is large for a series of matched
brain metastases, provides informative data and reports novel
findings. Furthermore, while one may make inferences regarding
the applicability of these observations to anti-VEGF therapy using
preclinical data (Huang et al, 2004; Mancuso et al, 2006) and
clinical data from other tumours (Willett et al, 2004), only serial
biopsies of brain metastases from patients receiving bevacizumab
will provide a definitive answer. To date, the two reported series of
NSCLC brain metastases treated with bevacizumab in the literature
are small, n¼36 (Besse et al, 2010) and n¼115 (Socinski et al,
2009) and provide no histopathological data. Moreover, it is
unlikely that clinicians would want to subject terminally ill patients
to repeated invasive procedures to provide such material.
In conclusion, brain metastases of NSCLCs have a vascular
phenotype that is distinct from the primary tumours. This has
implications for the use of anti-VEGF therapy in this setting and
should be taken into consideration when designing clinical trials to
assess the efficacy of such drugs and biomarkers that may predict
benefit.
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